SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy

Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering age...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Int J Mol Sci
Auteurs principaux: Kawanami, Daiji, Matoba, Keiichiro, Takeda, Yusuke, Nagai, Yosuke, Akamine, Tomoyo, Yokota, Tamotsu, Sango, Kazunori, Utsunomiya, Kazunori
Format: Artigo
Langue:Inglês
Publié: MDPI 2017
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5454992/
https://ncbi.nlm.nih.gov/pubmed/28524098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18051083
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires